Top Ten most popular articles on Pharmafile.com this week
pharmafile | February 10, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | biggest news, biggest stories, top 10, top 10 stories, top stories, top ten
Two of our top five stories this month are about one company in particular – a company that’s having a particularly tough time of late. Alongside this news, there are several stories on new approvals and exciting research in the Alzheimer’s field.
We arranged the top five European countries by the levels of expenditure upon pharmaceuticals, not all are from the largest countries, by population, and there’s a surprise omission.
BMS’ Opdivo further expands its label with an indication for bladder cancer via an intravenous injection, to add a slice of good news to an otherwise tough period for teh drug.
Worrying news in the battle against antibiotic-resistant bacteria, as a study from Cardiff University finds that the bacteria are being spread by flies and swallows to the human population.
As the world’s drug consumption continues to rise alongside advancements in the medical and pharmaceutical industries, so too do new challenges. And as technology also evolves, new solutions are coming into focus. But they are not without their own challenges, as Matt Fellows discovers.
Danish pharma firm Lundbeck has announced the failure of two Phase 3 trials investigating its experimental Alzheimer’s treatment idalopirdine.
Mentor Worldwide, a unit of US pharma firm Johnson & Johnson, has been accused of selling defective breast implants and is currently engaged in legal action over alleged health problems faced by a number of women.
Bayer have gained a boost to its blockbuster drug, Xarelto, with the successful early termination of a clinical trial due to it hitting its primary endpoint.
Teva was revealed to be under investigation by Israeli authorities following its settlement of a $519 million bribery fine.
Teva has announced a shift in corporate structure, as Erez Vigodman has left the company by “mutual agreement”. It comes after a particularly difficult year for Teva.
Researchers from the Stark Neurosciences Research Institute at Indiana University have claimed to have finally identified the purpose of an immune system protein that has divided scientists on its function within patients suffering from Alzheimer’s.
Among our ten most-read stories this week: NICE has announced that more patients are eligible …
In the last week, a number of COVID-19 new vaccine developments have been made. Pfizer …